Clinical Trial Update: Open-Label Safety Study of AXS-05 in Subjects With TRD (EVOLVE) [Phase 2]

View source ↗

Summary

An open-label Phase 2 safety study of AXS-05 in treatment-resistant depression and major depressive disorder was terminated, with results posted on 2026-01-28.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Major Depressive Disorder
• Treatment-resistant Depression

Drugs mentioned

• AXS-05 (dextromethorphan-quinidine)

Snippet

Sponsor: Axsome Therapeutics, Inc. | Conditions: Treatment Resistant Depression, Major Depressive Disorder | Phase 2 | Status: TERMINATED | Results posted: 2026-01-28